1. Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells
   TIANCHENG LIU et al, 2014 CrossRef
2. Prolonged androgen deprivation leads to overexpression of calpain 2: Implications for prostate cancer progression
   TIANCHENG LIU et al, 2014 CrossRef
3. Met in Urological Cancers
   Yasuyoshi Miyata et al, 2014, Cancers CrossRef
4. Testosterone serum levels and prostate cancer prognosis: the double face of Janus
   Francesca Valcamonico et al, 2014, Future Oncology CrossRef
5. Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level
   Theodoros Karantanos et al, 2015, European Urology CrossRef
6. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.
   Arndt Katzenwadel et al, 2015, Cancer Lett. CrossRef
7. The andrologist's contribution to a better life for ageing men: part 1
   F. Comhaire et al, 2016, Andrologia CrossRef
8. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
   Yuanyuan Qiao et al, 2016, Neoplasia CrossRef
9. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial
   Raya Leibowitz-Amit et al, 2016, J Transl Med CrossRef
10. c-Met expression and activity in urogenital cancers – novel aspects of signal transduction and medical implications
    Ralf Hass et al, 2017, Cell Commun Signal CrossRef
11. Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer
    Izhar Batth et al, 2016, Oncotarget CrossRef
12. MET expression during prostate cancer progression
    Esther I. Verhoef et al, 2016, Oncotarget CrossRef
13. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
    David S. Hong et al, 2015, Oncotarget CrossRef
14. Photoreactive Molecular Glue for Enhancing the Efficacy of DNA Aptamers by Temporary-to-Permanent Conjugation with Target Proteins
    Ai Kohata et al, 2021, J. Am. Chem. Soc. CrossRef
15. MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways.
    Sihai Zhou et al, 2021, J Cell Mol Med CrossRef
16. AR imposes different effects on ZFHX3 transcription depending on androgen status in prostate cancer cells
    Xing Fu et al, 2021, J Cellular Molecular Medi CrossRef
17. Evodiamine as the Active Compound of Evodiae fructus to Inhibit Proliferation and Migration of Prostate Cancer through PI3K/AKT/NF-κB Signaling Pathway
    Yuhe Lei et al, 2022, Disease Markers CrossRef
18. Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy
    Mikolaj J. Filon et al, 2022, The Prostate CrossRef
19. Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation
    Won Kyung Kim et al, 2024, Nat Commun CrossRef